CN
Search Within
H0165
应用筛选条件
关键词:'H0165'
显示 1-30 共 146 条结果 关于 "H0165" 范围 论文
Yusuke Sasaki et al.
Anticancer research, 34(4), 2029-2034 (2014-04-03)
Irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil administered every two weeks (FOLFIRI regimen) is active in patients with metastatic colorectal cancer. However, the efficacy and toxicity of this regimen in Japanese patients with metastatic colorectal cancer remain unknown. We investigated
Yuqin Yao et al.
Journal of controlled release : official journal of the Controlled Release Society, 220(Pt A), 5-17 (2015-10-07)
Antibody-drug conjugates (ADCs), combining monoclonal antibody with high cytotoxicity chemotherapeutic drug (warhead), have been successfully applied for clinical cancer therapy. Linker technology to select and design linker connecting warhead with antibody, is critical to the success of therapeutic ADCs. In
María Ramos Zapatero et al.
Cell, 186(25), 5606-5619 (2023-12-09)
Patient-derived organoids (PDOs) can model personalized therapy responses; however, current screening technologies cannot reveal drug response mechanisms or how tumor microenvironment cells alter therapeutic performance. To address this, we developed a highly multiplexed mass cytometry platform to measure post-translational modification
Takehiro Takahashi et al.
Gan to kagaku ryoho. Cancer & chemotherapy, 41(5), 653-655 (2014-06-12)
A 51-year-old man presented with a chief complaint of constipation. Rectal cancer was detected up to 13 cm proximal to the anal verge. The cancer was a fully circumferential type II tumor that was accompanied by prostate invasion and lymph
Joel Ohana et al.
Oncotarget, 14, 688-699 (2023-07-03)
Members of the rat sarcoma viral oncogene (RAS) subfamily KRAS are frequently mutated oncogenes in human cancers and have been identified in pancreatic ductal, colorectal, and lung adenocarcinomas. In this study, we show that a derivative of the hormone peptide
S Cao et al.
British journal of cancer, 110(7), 1733-1743 (2014-03-13)
Identification and development of drugs that can effectively modulate the therapeutic efficacy and toxicity of chemotherapy remain an unmet challenge. We evaluated the effects of Se-methylselenocysteine (MSC) on the toxicity and antitumour activity of cyclophosphamide, cisplatin, oxaliplatin, and irinotecan in
Jorge Barbazán et al.
International journal of cancer, 135(11), 2633-2643 (2014-04-23)
Circulating tumor cells (CTCs), proposed as major players in cancer dissemination, have demonstrated clinical prognostic significance in several cancer types. However, their predictive value remains unclear. Here we evaluated the clinical utility of six CTC markers (tissue specific and epithelial
Yoshiyuki Shishido et al.
Anticancer research, 33(4), 1379-1386 (2013-04-09)
The aim of this study was to determine the efficacy of the combination of irinotecan and newly-synthesized ABCG2 (breast cancer-resistant protein) inhibitor YHO-13351 in cancer chemotherapy. Side population (SP) and non-SP cells from the human cervical carcinoma cell line HeLa
Burcu Erbaykent-Tepedelen et al.
The Journal of steroid biochemistry and molecular biology, 141, 26-36 (2014-01-18)
It has been reported that NKX3.1 an androgen-regulated homeobox gene restricted to prostate and testicular tissues, encodes a homeobox protein, which transcriptionally regulates oxidative damage responses and enhances topoisomerase I re-ligation by a direct interaction with the ATM protein in
Sachiko Hirai et al.
PloS one, 9(7), e102831-e102831 (2014-07-18)
Up-regulated sirtuin 1 (SIRT1), an NAD+-dependent class III histone deacetylase, deacetylates p53 and inhibits its transcriptional activity, leading to cell survival. SIRT1 overexpression has been reported to predict poor survival in some malignancies, including gastric cancer. However, the antitumor effect
Min H Kang et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 21(5), 1139-1150 (2015-03-04)
To determine the pharmacokinetics and the antitumor activity in pediatric cancer models of MM-398, a nanoliposomal irinotecan (nal-IRI). Mouse plasma and tissue pharmacokinetics of nal-IRI and the current clinical formulation of irinotecan were characterized. In vivo activity of irinotecan and
Kyu-pyo Kim et al.
Cancer chemotherapy and pharmacology, 71(6), 1609-1617 (2013-04-19)
UGT1A1 genotypes are important when considering treatment with irinotecan-containing regimens. In this study, we determined the dose, efficacy, and tolerability of irinotecan according to UGT1A1 genotypes when combined with capecitabine in patients with metastatic colorectal cancer. Patients with histologically confirmed
Shigeyoshi Iwamoto et al.
Anticancer research, 34(4), 1967-1973 (2014-04-03)
This study was the first multicenter phase II study of cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type mCRC as a second-line treatment in Japan including BRAF and PIK3CA genotyping. Tumors of 112 pre-registered patients were genotyped for KRAS, BRAF
Lauriane Goldwirt et al.
Cancer chemotherapy and pharmacology, 74(1), 185-193 (2014-05-29)
Glioblastoma (GBM), the most common primary brain tumor in adults, is usually rapidly fatal with median survival duration of only 15 months and a 3-year survival rate of <7 %. Temozolomide (TMZ) is the only anticancer drug that has improved
Osamu Saji et al.
Gan to kagaku ryoho. Cancer & chemotherapy, 40(10), 1409-1412 (2013-11-08)
A case of recurrent pancreatic cancer effectively responded to S-1 and irinotecan combined with third-line chemotherapy (IRIS) with PSK. The patient was a 75-year-old female. In October 2007, a pancreatoduodenectomy was performed, followed with 6 courses of systemic adjuvant chemotherapy
The circadian rest-activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy.
Elisabet Ortiz-Tudela et al.
International journal of cancer, 134(11), 2717-2725 (2014-02-11)
The robustness of the circadian timing system (CTS) was correlated to quality of life and predicted for improved survival in cancer patients. However, chemotherapy disrupted the CTS according to dose and circadian timing in mice. A continuous and repeated measures
Ashish V Kalra et al.
Cancer research, 74(23), 7003-7013 (2014-10-03)
A major challenge in the clinical use of cytotoxic chemotherapeutics is maximizing efficacy in tumors while sparing normal tissue. Irinotecan is used for colorectal cancer treatment but the extent of its use is limited by toxic side effects. Liposomal delivery
Chien-Yu Lu et al.
Translational research : the journal of laboratory and clinical medicine, 164(2), 169-176 (2014-01-28)
This study compared the clinical responses of patients with metastatic colorectal cancer (mCRC) with 5-fluorouracil/leucovorin with irinotecan (FOLFIRI) plus bevacizumab therapy either with or without uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping and irinotecan dose escalation. Of 107 total patients with
Yukiko Tsukao et al.
Gan to kagaku ryoho. Cancer & chemotherapy, 40(12), 2451-2453 (2014-01-08)
We report a case of long-term survival after combination chemotherapy and surgical resection of a cancer of unknown primary site[ CUPs]. A septuagenarian female was identified as having high blood levels of carcinoembryonic antigen (CEA) during follow-up monitoring of asthma.
Michael I DʼAngelica et al.
Annals of surgery, 261(2), 353-360 (2014-03-22)
Evaluate conversion rate of patients with unresectable colorectal-liver metastasis to complete resection with hepatic-arterial infusion plus systemic chemotherapy including bevacizumab (Bev). Forty-nine patients with unresectable colorectal liver metastases (CRLM) were included in a single-institution phase II trial. Conversion to resection
Léa Payen et al.
Oncotarget, 5(23), 11957-11970 (2014-12-05)
ABCG2 is responsible for the multidrug resistance (MDR) phenotype, and strongly modulates cancer outcomes. Its high expression at a number of physiological barriers, including blood-brain and intestinal barriers, impacts on drug pharmacokinetics parameters. We characterized MBL-II-141, a specific and potent
Valerie B Sampson et al.
PloS one, 10(11), e0142704-e0142704 (2015-11-17)
Histone deacetylase inhibitors (HDACi) have been evaluated in patients with Ewing sarcoma (EWS) but demonstrated limited activity. To better understand the potential for HDACi in EWS, we evaluated the combination of the HDACi vorinostat, with DNA damaging agents SN-38 (the
Pierre Michel et al.
European journal of cancer (Oxford, England : 1990), 50(6), 1076-1083 (2014-01-18)
For resectable gastric cancer, both postoperative chemoradiotherapy and perioperative chemotherapy demonstrate high-level evidence for improved survival in Western populations. To evaluate the feasibility of pre- or postoperative chemoradiotherapy, we proposed two multicentre phase II studies. Patients with localised, histologically confirmed
Hirofumi Yasui et al.
Journal of cancer research and clinical oncology, 141(1), 153-160 (2014-08-12)
The FIRIS study previously demonstrated non-inferiority of IRIS (irinotecan plus S-1) to FOLFIRI (5-fluorouracil/leucovorin with irinotecan) for progression-free survival as the second-line chemotherapy for metastatic colorectal cancer (mCRC) as the primary endpoint. The overall survival (OS) data were immature at
Toshihiro Nishizawa et al.
Gan to kagaku ryoho. Cancer & chemotherapy, 40(6), 807-809 (2013-07-19)
The patient was a 78-year-old woman who suffered from right upper quadrant pain. She was diagnosed as colon cancer with hepatic metastasis. Initial chemotherapy using capecitabine plus oxaliplatin(XELOX)+bevacizumab achieved partial response. After 12 months, XELOX was discontinued due to Grade
Amy B Hall et al.
Oncotarget, 5(14), 5674-5685 (2014-07-11)
Platinum-based DNA-damaging chemotherapy is standard-of-care for most patients with lung cancer but outcomes remain poor. This has been attributed, in part, to the highly effective repair network known as the DNA-damage response (DDR). ATR kinase is a critical regulator of
Elsa Hadj Bachir et al.
Biology of the cell, 114(1), 32-55 (2021-09-26)
Although improvements have been made in the management of pancreatic adenocarcinoma (PDAC) during the past 20 years, the prognosis of this deadly disease remains poor with an overall 5-year survival under 10%. Treatment with FOLFIRINOX, a combined regimen of 5-fluorouracil
Koji Yamanoi et al.
Gynecologic oncology, 131(3), 701-707 (2013-10-23)
The sensitivity of the current 10mm cut-off diameter that is used to diagnose lymph node (LN) metastasis is too low. This is the first study to develop a new criterion to diagnose LN metastasis in a region-by-region manner using multi-detector
Satoshi Yamasaki et al.
Annals of hematology, 94(1), 65-69 (2014-07-25)
The uridine diphosphate glucuronosyltransferase (UGT) gene 1A1*6 polymorphism, which affects irinotecan metabolism, has been associated with improved survival in lymphoma patients treated with of carboplatin, dexamethasone, etoposide and irinotecan (CDE-11). This study assessed the efficacy of CDE-11 relative to the
Osamu Kinoshita et al.
Gan to kagaku ryoho. Cancer & chemotherapy, 40(12), 1623-1625 (2014-01-08)
In recent years, with the increase in the adoption of anus-preserving surgery, understanding of residual lower rectal cancer distribution to the anal side after chemoradiotherapy (CRT) has become an increasingly important issue. We aimed to clarify the pathological safe distal
1/5